A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and a...
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children a...
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome....
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged ≥6 to \<36 months (Part 1) and aged ≥6 to \<48...
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in ...
Top Cities for Dravet Syndrome Clinical Trials
Dravet Syndrome clinical trials are recruiting across 23 cities. Here are the cities with the most active studies:
About Dravet Syndrome
Dravet syndrome is a rare, severe form of epilepsy that begins in the first year of life with prolonged seizures often triggered by fever. It is usually caused by mutations in the SCN1A gene. Treatment includes specific antiseizure medications, avoiding certain drugs that can worsen seizures, and investigational gene therapies.
Clinical trials are advancing new treatments for dravet syndrome. Currently, 5 studies are recruiting a combined 494 participants across the United States. Research is being conducted by 5 organizations including Longboard Pharmaceuticals, Epygenix, Stoke Therapeutics, Inc and 2 others.
2026 Dravet Syndrome Research Landscape
As of March 2026, the dravet syndrome clinical trial landscape includes 5 actively recruiting studies across 23 cities in the United States. These studies are collectively seeking 494 participants, with an average enrollment target of 99 per study.
Research is being led by 5 different organizations, including Longboard Pharmaceuticals, Epygenix, Stoke Therapeutics, Inc, Encoded Therapeutics, University of Colorado, Denver.
Geographically, dravet syndrome trials are most concentrated in San Francisco, California (5 trials); Aurora, Colorado (3 trials); Little Rock, Arkansas (2 trials); Orlando, Florida (2 trials); Atlanta, Georgia (2 trials) and 7 other cities.
Featured Dravet Syndrome Studies
Highlighted recruiting studies for dravet syndrome, selected by enrollment size and research scope.
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. ...
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
This is a multicenter, Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of clemizole hydrochloride (EPX-100) as adjunctive therapy in children and adult participants with Dravet syndrome (DS).
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Frequently Asked Questions About Dravet Syndrome Clinical Trials
Are there dravet syndrome clinical trials near me?
Yes, there are 5 dravet syndrome clinical trials currently recruiting across 23+ cities in the United States, including San Francisco, California; Aurora, Colorado; Little Rock, Arkansas. Browse the studies above to find one at a location convenient for you.
How do I join a dravet syndrome clinical trial?
To join a dravet syndrome clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are dravet syndrome clinical trials free?
Yes, participation in dravet syndrome clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of dravet syndrome treatments are being studied?
Current dravet syndrome clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 5 research organizations.
Is it safe to participate in dravet syndrome clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov